Trials / Not Yet Recruiting

Not Yet RecruitingNCT07243340

A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Herpes Virus C5252 Injection in Patients With Intracranial Tumor

Status: Not Yet Recruiting
Phase: Phase 1 / Phase 2
Study type: Interventional
Enrollment: 36 (estimated)

Sponsor: ImmVira Pharma Co. Ltd · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.

Conditions

Glioma, Malignant

Interventions

Type	Name	Description
BIOLOGICAL	Herpes Virus C5252 Injection	C5252 will be administered at designed dose level.

Timeline

Start date: 2025-12-15
Primary completion: 2027-12-15
Completion: 2028-12-15
First posted: 2025-11-21
Last updated: 2025-11-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07243340. Inclusion in this directory is not an endorsement.